特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

生物学的製剤の知的財産権:戦略的レビュー

Biologics IP - A Strategic Review

発行 Frost & Sullivan 商品コード 370700
出版日 ページ情報 英文 71 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=107.71円で換算しております。
生物学的製剤の知的財産権:戦略的レビュー Biologics IP - A Strategic Review
出版日: 2016年08月10日 ページ情報: 英文 71 Pages
概要

当レポートでは、大手医薬品・バイオテクノロジー企業13社による生物学的製剤関連の特許について調査し、製剤タイプ・治療分野別の特許ポートフォリオのマッピング、競合ベンチマーキングなどをまとめています。

第1章 エグゼクティブサマリー

第2章 調査目的・背景

  • 調査目的
  • 生物学的製剤 vs 小分子
  • 大手医薬品製造業者による小分子から生物学的製剤への移行とその理由
  • M&Aによって生物学的製剤の専門性を獲得する大手医薬品製造業者

第3章 調査範囲・調査手法

第4章 医薬品大手13社の生物学的製剤の特許ポートフォリオ

  • 医薬品大手13社の競合ベンチマーキング:生物学的製剤の特許ポートフォリオ

第5章 生物学的製剤の特許ポートフォリオ:概要

  • ROCHE
  • GSK
  • MERCK
  • SANOFI
  • NOVARTIS
  • BRISTOL-MYERS SQUIBB
  • AMGEN
  • NOVO NORDISK
  • PFIZER
  • ELI LILLY
  • ASTRAZENECA
  • BAYER HEALTHCARE
  • ABBVIE
    • 特許ポートフォリオマッピング:生物学的製剤タイプ別
    • 特許ポートフォリオマッピング:治療分野別

第6章 主要調査結果

第7章 付録

  • 用語

第8章 FROST & SULLIVANについて

目次
Product Code: D6AE-01-00-00-00

Profiling Patenting Activity of 13 Major Pharma-biotech Companies in the Area of Biologics

This study provides a strategic overview of the patent activity of the 13 major pharma-biotech companies in the area of biologics. The biologics patent portfolios of these companies were analyzed and segmented by biologics type (e.g., peptides, antibodies, vaccines etc.) and therapeutic area for competitive benchmarking. This study will help pharma-biotech companies understand the competitive landscape and the available white space from patenting perspective.

Table of Contents

1 1.0 EXECUTIVE SUMMARY

  • 1.0 Executive Summary

2 2.0 RESEARCH OBJECTIVE AND BACKGROUND

  • 2.1 Research Objective
  • 2.2 Biologics versus Small Molecule
  • 2.3 Big Pharma Shifting Focus from Small Molecule to Biologics, Why?
  • 2.4 Big Pharma Gained Biologics Expertise through Mergers and Acquisitions (M&A)-Important Deals

3 3.0 RESEARCH SCOPE AND METHODOLOGY

  • 3.1 Research Scope and Concepts
  • 3.2 Analysis Approach
  • 3.3 Keywords and IPC Codes Used for Clustering by Biologics Type
  • 3.4 Therapeutic Areas Covered in the Study

4 4.0 BIOLOGICS PATENT PORTFOLIOS OF THE TOP 13 MAJOR PHARMA COMPANIES

  • 4.1 Competitive Benchmarking of the Top 13 Major Pharma Companies Based on Their Biologics Patent Portfolios, 1996-2015

5 5.0 OVERVIEW OF BIOLOGICS PATENT PORTFOLIO5.1 COMPANY 1: ROCHE

  • 5.1.1 Mapping of Roche's Patent Portfolio by Biologics Type
  • 5.1.2 Mapping of Roche's Patent Portfolio by Therapeutic Area

6 5.2 COMPANY 2: GSK

  • 5.2.1 Mapping of GSK's Patent Portfolio by Biologics Type
  • 5.2.2 Mapping of GSK's Patent Portfolio by Therapeutic Area

7 5.3 COMPANY 3: MERCK

  • 5.3.1 Mapping of Merck's Patent Portfolio by Biologics Type
  • 5.3.2 Mapping of Merck's Patent Portfolio by Therapeutic Area

8 5.4 COMPANY 4: SANOFI

  • 5.4.1 Mapping of Sanofi's Patent Portfolio by Biologics Type
  • 5.4.2 Mapping of Sanofi's Patent Portfolio by Therapeutic Area

9 5.5 COMPANY 5: NOVARTIS

  • 5.5.1 Mapping of Novartis's Patent Portfolio by Biologics Type
  • 5.5.2 Mapping of Novartis's Patent Portfolio by Therapeutic Area

10 5.6 COMPANY 6: BRISTOL-MYERS SQUIBB

  • 5.6.1 Mapping of Bristol-Meyers Squibb's Patent Portfolio by Biologics Type
  • 5.6.2 Mapping of Bristol-Meyers Squibb's Patent Portfolio by Therapeutic Area

11 5.7 COMPANY 7: AMGEN

  • 5.7.1 Mapping of Amgen's Patent Portfolio by Biologics Type
  • 5.7.2 Mapping of Amgen's Patent Portfolio by Therapeutic Area

12 5.8 COMPANY 8: NOVO NORDISK

  • 5.8.1 Mapping of Novo Nordisk's Patent Portfolio by Biologics Type
  • 5.8.2 Mapping of Novo Nordisk's Patent Portfolio by Therapeutic Area

13 5.9 COMPANY 9: PFIZER

  • 5.9.1 Mapping of Pfizer's Patent Portfolio by Biologics Type
  • 5.9.2 Mapping of Pfizer's Patent Portfolio by Therapeutic Area

14 5.10 COMPANY 10: ELI LILLY

  • 5.10.1 Mapping of Eli Lilly's Patent Portfolio by Biologics Type
  • 5.10.2 Mapping of Eli Lilly's Patent Portfolio by Therapeutic Area

15 5.11 COMPANY 11: ASTRAZENECA

  • 5.11.1 Mapping of AstraZeneca's Patent Portfolio by Biologics Type
  • 5.11.2 Mapping of AstraZeneca's Patent Portfolio by Therapeutic Area

16 5.12 COMPANY 12: BAYER HEALTHCARE

  • 5.12.1 Mapping of Bayer HealthCare's Patent Portfolio by Biologics Type
  • 5.12.2 Mapping of Bayer HealthCare's Patent Portfolio by Therapeutic Area

17 5.13 COMPANY 13: ABBVIE

  • 5.13.1 Mapping of AbbVie's Patent Portfolio by Biologics Type
  • 5.13.2 Mapping of AbbVie's Patent Portfolio by Therapeutic Area

18 6.0 KEY FINDINGS

  • 6.1 Key Findings
  • Legal Disclaimer

19 7.0 APPENDIX

  • 7.1 Acronyms

20 8.0 THE FROST & SULLIVAN STORY

  • 8.1 The Frost & Sullivan Story
  • 8.2 Value Proposition: Future of Your Company & Career
  • 8.3 Global Perspective
  • 8.4 Industry Convergence
  • 8.5 360° Research Perspective
  • 8.6 Implementation Excellence
  • 8.7 Our Blue Ocean Strategy